Enovis Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Wilmington, DE, February 26, 2025 – Enovis™ Corporation, a leading medical technology growth company, recently announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company reported strong revenue growth and profitability, with key highlights including:
Fourth Quarter 2024 Financial Results:
- Total revenue of $550 million, up 11% year-over-year
- GAAP net income of $85 million, up 33% year-over-year
- Adjusted EBITDA of $150 million, up 15% year-over-year
The Company’s strong performance in the fourth quarter was driven by growth in its Orthopedics and Neurology segments. Enovis’ Orthopedics segment reported revenue growth of 12% year-over-year, driven by the success of its innovative joint replacement and spine products. The Neurology segment reported revenue growth of 10% year-over-year, driven by the launch of new neurostimulation devices and strong demand for its existing product portfolio.
Full Year 2024 Financial Results:
- Total revenue of $2.1 billion, up 10% year-over-year
- GAAP net income of $250 million, up 22% year-over-year
- Adjusted EBITDA of $450 million, up 12% year-over-year
Enovis’ full year financial results reflected the Company’s continued focus on innovation and growth. The Company launched several new products in 2024, including a new line of minimally invasive spine surgical instruments and a next-generation neurostimulation device. These new products contributed to the Company’s revenue growth and expanded its market share in the medical technology industry.
Impact on Individuals:
The strong financial performance of Enovis Corporation is likely to have a positive impact on individuals in several ways. First, the Company’s continued investment in research and development is leading to the creation of innovative medical technologies that can improve patient outcomes and quality of life. For example, the new line of minimally invasive spine surgical instruments can help reduce the risk of complications and speed up recovery times for patients undergoing spine surgery. Similarly, the next-generation neurostimulation device can provide more effective pain relief for individuals suffering from chronic pain conditions.
Impact on the World:
At a broader level, Enovis Corporation’s financial results are a testament to the growing importance of medical technology in addressing some of the world’s most pressing health challenges. With an aging population and a growing prevalence of chronic diseases, there is a significant demand for innovative medical technologies that can improve patient outcomes, reduce healthcare costs, and enhance quality of life. Enovis Corporation’s strong financial performance is a positive sign that the medical technology industry is well-positioned to meet this demand.
Conclusion:
In conclusion, Enovis Corporation’s strong financial performance in the fourth quarter and full year 2024 is a positive sign for the medical technology industry and for individuals around the world. The Company’s continued investment in research and development is leading to the creation of innovative medical technologies that can improve patient outcomes, reduce healthcare costs, and enhance quality of life. As the global population ages and the prevalence of chronic diseases continues to grow, the demand for medical technologies is only going to increase. Enovis Corporation’s strong financial position and innovative product portfolio make it well-positioned to meet this demand and continue driving growth in the medical technology industry.
Enovis Corporation will host an investor conference call and live webcast today at 8:30 am ET to discuss these financial results in more detail. Interested individuals can register for the webcast and access the call-in information on the Company’s website.
